(DPRX) Announces Participation in Four Investor Conferences in September

NEW YORK, Aug. 31, 2015  — Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide, today announced plans to participate in four investor conferences in September.

• Wednesday, September 2, 2015 at the Sidoti & Company, LLC Emerging Growth Conference in New York City. David P. Luci, President & Chief Executive Officer, will present a corporate overview at 8:00 a.m. ET.
• Wednesday, September 9, 2015 at the Rodman & Renshaw 17^th Annual Global Investment Conference in New York City. David P. Luci, President & Chief Executive Officer, will present a corporate overview at 9:10 a.m. ET. To access the live audio webcast of this presentation, please log on through a link located in the Investor Relations section of Dipexium’s website at www.dipexiumpharmaceuticals.com, under the IR Calendar tab. A replay of the webcast will be available for 30 days after the conclusion of the live event.
• Wednesday, September 9, 2015 at the FBR Second Annual Healthcare Conference in Boston. David Garrett, Vice President, Finance & Corporate Development will attend and participate in institutional investor meetings.
• Thursday, September 10, 2015 at the NewsMakers in the Biotech Industry in New York City. David Garrett, Vice President, Finance & Corporate Development will attend and participate in institutional investor meetings.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the U.S. federal securities laws.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions.  These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission and those that relate to the Company’s ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contacts:

David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
info@dipexium.com

David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
info@dipexium.com

Investor Relations Contact:

Donna L. LaVoie or Kristina Coppola
LaVoie Health Science
617-374-8800 X107/105
kcoppola@lavoiehealthscience.com